DCM
SNDX icon

DAFNA Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

DAFNA Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.33M Buy
335,255
+117,900
+54% +$2.45M 1.4% 19
2026
Q1 		$5.08M Sell
217,355
-60,500
-22% -$1.31M 1.16% 27
2025
Q4 		$5.84M Sell
277,855
-222,847
-45% -$3.89M 1.36% 17
2025
Q3 		$7.7M Sell
500,702
-42,900
-8% -$562K 1.9% 13
2025
Q2 		$5.09M Sell
543,602
-900
-0.2% -$9.91K 1.41% 20
2025
Q1 		$6.69M Buy
544,502
+2,500
+0.5% +$35.3K 1.9% 15
2024
Q4 		$7.17M Buy
542,002
+15,300
+3% +$262K 1.82% 17
2024
Q3 		$10.1M Sell
526,702
-130,372
-20% -$2.69M 2.4% 14
2024
Q2 		$13.5M Sell
657,074
-2,500
-0.4% -$52.3K 3.22% 9
2024
Q1 		$15.7M Sell
659,574
-83,000
-11% -$1.85M 3.57% 8
2023
Q4 		$16M Buy
742,574
+284,201
+62% +$4.37M 3.85% 5
2023
Q3 		$6.66M Buy
458,373
+7,500
+2% +$142K 2.07% 14
2023
Q2 		$9.44M Buy
450,873
+3,800
+0.8% +$79.1K 2.58% 13
2023
Q1 		$9.44M Hold
447,073
– – 2.83% 11
2022
Q4 		$11.4M Buy
447,073
+91,586
+26% +$2.14M 3.2% 10
2022
Q3 		$8.54M Sell
355,487
-15,500
-4% -$348K 2.3% 12
2022
Q2 		$7.14M Sell
370,987
-1,000
-0.3% -$16.7K 1.95% 15
2022
Q1 		$6.46M Buy
371,987
+75,452
+25% +$1.27M 1.68% 16
2021
Q4 		$6.49M Buy
296,535
+215,833
+267% +$3.99M 1.63% 16
2021
Q3 		$1.54M Sell
80,702
-67,000
-45% -$1.12M 0.41% 58
2021
Q2 		$2.54M Buy
147,702
+90,202
+157% +$1.65M 0.53% 42
2021
Q1 		$1.29M Buy
57,500
+47,500
+475% +$1.07M 0.31% 68
2020
Q4 		$222K Sell
10,000
-92,713
-90% -$1.92M 0.07% 72
2020
Q3 		$1.52M Sell
102,713
-257,287
-71% -$3.92M 0.49% 44
2020
Q2 		$5.33M Buy
+360,000
New +$5.48M 1.54% 20

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

DAFNA Capital Management's SNDX Position: Q2 2026 in Review

DAFNA Capital Management increased its Syndax Pharmaceuticals (SNDX) stake by 54% in Q2 2026, buying an estimated $2.45M and bringing the position to 335,255 shares worth $7.33M. The position accounts for 1.4% of the portfolio, ranked #19.

DAFNA Capital Management first reported a position in SNDX in Q2 2020 and has held it in 25 quarters since. The position peaked at $16M in Q4 2023. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • DAFNA Capital Management held 335,255 shares of Syndax Pharmaceuticals worth $7.33M as of Q2 2026.
  • DAFNA Capital Management bought 117,900 Syndax Pharmaceuticals shares in Q2 2026, an estimated $2.45M.
  • Syndax Pharmaceuticals made up 1.4% of DAFNA Capital Management's portfolio in Q2 2026, its #19 holding.
  • DAFNA Capital Management first reported a position in Syndax Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • DAFNA Capital Management's Syndax Pharmaceuticals position peaked at $16M in Q4 2023.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on DAFNA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.